i-Lumen Scientific, Inc. Obtains Colombia Approval for its i-Sight 2 Clinical Study

Jan 17

Bogota, Colombia. On January 17, 2024, INVIMA, the regulatory agency of Colombia, approved i-Lumen Scientific, Inc.'s i-Sight 2 study, which will be conducted at two research centers located in Medellín and Cali. The i-Sight clinical trial aims to recruit up to 75 subjects from Colombia and will last for approximately 27 months. i-Lumen Scientific, Inc. is a company that specializes in developing medical devices to prevent vision loss and blindness. Their approach involves using non-invasive transpalpebral (surface) microcurrent technology. Their primary focus is on developing non-invasive therapy for dry age-related macular degeneration (AMD), which is a common eye condition among the elderly and can cause significant vision loss. The company's innovative solution involves a unique surface neurostimulation technology called Neural Retinal Therapy™, which has been designed to restore vision in individuals suffering from dry AMD.

Source: INVIMA's Medical Device Committee, January 17, 2024 meeting minutes.

i-Lumen Scientifici-Sight 2 Studyi-Lumen® AMDMedical device CRO in Latin AmericaFirs-in-human studyClinical research in Latin AmericaClinical trials in Latin AmericaEarly-feasibility clinical trialsEarly feasibility studyMedtech clinical trialsColombia

Julio G. Martinez-Clark http://www.juliomartinezclark.com/

i-Lumen Scientific, Inc. Obtains Colombia Approval for its i-Sight 2 Clinical Study

eyeFlow, Inc. Obtains Colombia Approval for its Pilot Clinical Study

3ive Labs Obtains Colombia Approval for its BIPASS-AKI 2 Study